Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Companhia de Saneamento Bsico do Estado de So Paulo  SABESP provides water and sewage services to residential, commercial, industrial, and governmental customers. It provides water supply, sanitary sewage, urban rainwater management and drainage, urban cleaning, and solid waste management services, as well as related activities, including the planning, operation, maintenance, and commercialization of energy. As of December 31, 2021, the company provided water services through 9.8 million water connections to approximately 27.8 million people; sewage services through 8.4 million sewage connections to approximately 24.6 million people; and operated 88,904 kilometers of water pipes and water transmission lines, as well as 61,122 kilometers of sewer lines. It also offers water and/or sewage services to four other municipalities through special purpose companies. The company was founded in 1954 and is headquartered in So Paulo, Brazil.

Companhia de Saneamento Bsico do Estado de So Paulo - SABESP

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PREMIER LATINO AUDIOVISUAL ENTERTAINMENT DESTINATION TO REACH MILLIONS OF SPANISH-SPEAKING VIEWERS MIAMI , JUNE 9, 2025 /PRNEWSWIRE/ -- SPANISH BROADCASTING SYSTEM, INC. (SBS), THE LARGEST HISPANIC-CONTROLLED MEDIA AND ENTERTAINMENT COMPANY IN THE UNITED STATES, TODAY ANNOUNCED THAT LAMUSICA, ITS TOP-RANKED AUDIOVISUAL ENTERTAINMENT APP, WILL BEGIN LIVESTREAMING AS LAMUSICA TV ON THE ROKU CHANNEL. THIS SUMMER, MILLIONS OF ROKU'S HISPANIC CUSTOMERS IN THE U.S. AND MEXICO WILL GAIN ACCESS TO LAMUSICA TV VIA THE ROKU CHANNEL, THE #2 APP ON THE ROKU PLATFORM IN THE U.S. BY ENGAGEMENT.

SBS ANNOUNCES GROUNDBREAKING PARTNERSHIP WITH THE ROKU CHANNEL FOR LIVESTREAMING THE NEW LAMUSICA TV

SAN JUAN, PUERTO RICO , JUNE 5, 2025 /PRNEWSWIRE/ -- SPANISH BROADCASTING SYSTEM, INC. (SBS), THE LARGEST MINORITY-OWNED HISPANIC MEDIA COMPANY IN THE U.S., HAS ENTERED INTO AN ASSET PURCHASE AGREEMENT FOR THE SALE OF WVEO(DT), WTCV(DT), AND WVOZ-TV PUERTO RICO TO WORD OF GOD FELLOWSHIP, INC., A CHRISTIAN FAITH-BASED BROADCAST OWNER-OPERATOR KNOWN AS DAYSTAR TELEVISION NETWORK. THIS STRATEGIC SALE REINFORCES SBS'S FOCUS ON ITS CORE AUDIO AND DIGITAL BUSINESSES, CONTINUING SBS'S INDUSTRY-LEADING RADIO PORTFOLIO DOMINANCE (INCLUDING THE MOST-LISTENED-TO-AND-STREAMED STATION IN THE NATION, WSKQ-FM, IN NEW YORK CITY), ALONG WITH ITS DIGITAL PLATFORMS (AMONG WHICH IS INCLUDED THE HIGHEST-RATED LATINO MUSIC STREAMING APP, LAMUSICA) IN FURTHER SERVING AND EMPOWERING HISPANIC AUDIENCES ACROSS THE US AND PUERTO RICO FOOTPRINTS.

SPANISH BROADCASTING SYSTEM SELLS PUERTO RICO TV TO CHRISTIAN MEDIA GROUP

JAGUAR TO HOST INVESTOR WEBCAST TODAY AT 8:30 AM EASTERN TO REVIEW THE INITIAL RESULTS FROM THE PROOF-OF-CONCEPT STUDY OF CROFELEMER FOR MVID AND SBS-IF PRESENTED APRIL 26 AT THE ANNUAL ELITE PED-GI CONGRESS ; CLICK HERE TO REGISTER THERE ARE NO APPROVED DRUG TREATMENTS FOR MVID, AN ULTRARARE PEDIATRIC DISEASE CHARACTERIZED BY SEVERE DIARRHEA AND MALABSORPTION THAT REQUIRES INTENSIVE PARENTERAL SUPPORT FOR NUTRITIONAL AND FLUID MANAGEMENT INCLUDING TOTAL PARENTERAL NUTRITION (TPN) - WHICH CARRIES THE RISK OF MORBIDITY, INFECTIONS, METABOLIC COMPLICATIONS, LIVER AND KIDNEY PROBLEMS, AND NEURODEVELOPMENTAL DELAY THIS PROOF-OF-CONCEPT DATA IN MVID SUPPORTS CROFELEMER'S POTENTIAL INCLUSION IN THE EUROPEAN MEDICINES AGENCY'S (EMA) PRIME PROGRAM FOR EXPEDIATED AND ASSISTED REGULATORY APPROVAL IN THE EU AS WELL AS FDA'S BREAKTHROUGH THERAPIES PROGRAM FOR EXPEDITED REGULATORY APPROVAL IN THE US SAN FRANCISCO, CA / ACCESS NEWSWIRE / APRIL 30, 2025 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) (JAGUAR) FAMILY COMPANIES NAPO PHARMACEUTICALS (NAPO) AND NAPO THERAPEUTICS TODAY ANNOUNCED INITIAL PROOF-OF-CONCEPT RESULTS SHOWING THAT A NOVEL LIQUID FORMULATION OF CROFELEMER REDUCED THE REQUIRED TPN AND/OR SUPPLEMENTARY INTRAVENOUS FLUIDS, COLLECTIVELY REFERRED TO AS PARENTERAL SUPPORT (PS) IN PATIENTS WITH INTESTINAL FAILURE DUE TO MICROVILLUS INCLUSION DISEASE (MVID) AND SHORT BOWEL SYNDROME (SBS-IF) BY UP TO 27% AND 12.5% RESPECTIVELY. IN ADDITION, THIS DATA SHOWED THAT CROFELEMER REDUCED STOOL VOLUME OUTPUT AND/OR FREQUENCY OF WATERY STOOLS, AND INCREASED URINE OUTPUT - AN INDICATOR OF IMPROVED NUTRIENT ORAL ABSORPTION.

PROOF-OF-CONCEPT RESULTS SHOW CROFELEMER REDUCED TOTAL PARENTERAL NUTRITION IN PATIENTS WITH RARE DISEASES MICROVILLUS INCLUSION DISEASE (MVID) AND SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) BY UP TO 27% AND 12.5% - POTENTIAL TO MODIFY DISEASE PROGRESSION IN INTESTINAL FAILURE PATIENTS

THE WEBCAST WILL REVIEW THE MVID AND SBS-IF PATIENT EXPERIENCE, THE IMPACT OF CROFELEMER ON DISEASE PROGRESSION AND QUALITY OF LIFE IN MVID AND SBS-IF, AND POSSIBLE EXPEDITED REGULATORY PATHWAYS FOR CROFELEMER FOR MVID; CLICK HERE TO REGISTER THERE ARE CURRENTLY NO APPROVED DRUG TREATMENTS FOR MVID, AN ULTRARARE PEDIATRIC DISEASE CHARACTERIZED BY SEVERE DIARRHEA AND MALABSORPTION THAT REQUIRES INTENSIVE PARENTERAL SUPPORT FOR NUTRITIONAL AND FLUID MANAGEMENT THIS DATA WAS PRESENTED AT THE ANNUAL ELITE PED-GI CONGRESS BY DR. MOHAMAD MIQDADY, A RECOGNIZED LEADER IN PEDIATRIC GASTROENTEROLOGY AND THE PRIMARY INVESTIGATOR FOR THIS STUDY SAN FRANCISCO, CA / ACCESS NEWSWIRE / APRIL 29, 2025 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) (JAGUAR) FAMILY COMPANIES NAPO PHARMACEUTICALS (NAPO) AND NAPO THERAPEUTICS TODAY ISSUED A REMINDER THAT JAGUAR IS HOSTING AN INVESTOR WEBCAST ON WEDNESDAY, APRIL 30, 2025 AT 8:30 AM EASTERN TO REVIEW THE INITIAL RESULTS OF THE PROOF-OF-CONCEPT INVESTIGATOR-INITIATED TRIAL OF A NOVEL LIQUID FORMULATION OF CROFELEMER, JAGUAR'S PLANT-BASED ANTI-SECRETORY PRESCRIPTION DRUG, IN PATIENTS WITH THE RARE DISEASES MICROVILLUS INCLUSION DISEASE (MVID) AND SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) THAT WERE PRESENTED BY DR. MOHAMAD MIQDADY ON APRIL 26, 2025 AT THE 11TH ANNUAL ELITE PED-GI CONGRESS IN ABU DHABI IN THE UNITED ARAB EMIRATES. PARTICIPATION INSTRUCTIONS FOR JAGUAR INVESTOR WEBCAST WHEN: WEDNESDAY, APRIL 30, 2025 AT 8:30 AM EASTERN TIME WHERE: ONLINE REGISTRATION LINK FOR CONFERENCE: CLICK HERE ABOUT CROFELEMER CROFELEMER IS A NOVEL, ORAL PLANT-BASED PRESCRIPTION MEDICINE PURIFIED FROM THE RED BARK SAP, ALSO REFERRED TO AS "DRAGON'S BLOOD," OF THE CROTON LECHLERI TREE IN THE AMAZON RAINFOREST.

REMINDER: JAGUAR HEALTH HOSTING APRIL 30 INVESTOR WEBCAST TO PRESENT INITIAL RESULTS FROM PROOF-OF-CONCEPT STUDY OF CROFELEMER FOR THE RARE DISEASES MICROVILLUS INCLUSION DISEASE (MVID) AND SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF)

CROFELEMER, A NOVEL PLANT-BASED ANTI-SECRETORY PRESCRIPTION DRUG, HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY THE FDA AND THE EUROPEAN MEDICINES AGENCY (EMA) FOR BOTH SHORT BOWEL SYNDROME (SBS) AND MICROVILLUS INCLUSION DISEASE (MVID) AND IS BEING EVALUATED TO SERVE AS A POTENTIAL THERAPEUTIC OPTION TO MANAGE INTESTINAL FAILURE IN THESE PATIENTS THERE ARE CURRENTLY NO APPROVED DRUG TREATMENTS FOR MVID, AN ULTRARARE PEDIATRIC DISEASE CHARACTERIZED BY SEVERE DIARRHEA AND MALABSORPTION THAT REQUIRES INTENSIVE PARENTERAL SUPPORT FOR NUTRITIONAL AND FLUID MANAGEMENT PROOF-OF-CONCEPT DATA IN MVID FROM THIS STUDY WOULD PROVIDE SUPPORT FOR CROFELEMER'S POTENTIAL INCLUSION IN THE EMA'S PRIME PROGRAM FOR NOVEL MEDICINES TARGETING UNMET MEDICAL NEEDS AND THE FDA'S BREAKTHROUGH THERAPIES PROGRAM SAN FRANCISCO, CA / ACCESS NEWSWIRE / APRIL 17, 2025 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) (JAGUAR) FAMILY COMPANIES NAPO PHARMACEUTICALS (NAPO) AND NAPO THERAPEUTICS TODAY ANNOUNCED THAT PRELIMINARY RESULTS FROM THE ONGOING PEDIATRIC INVESTIGATOR-INITIATED TRIAL (IIT) OF A NOVEL LIQUID FORMULATION OF CROFELEMER, JAGUAR'S NOVEL PLANT-BASED ANTI-SECRETORY PRESCRIPTION DRUG, FOR VARIOUS CONGENITAL DIARRHEAL DISORDERS (CDD), INCLUDING MVID AND SBS WITH INTESTINAL FAILURE (SBS-IF), WILL BE PRESENTED BY DR. MOHAMAD MIQDADY AT THE APRIL 24-26, 2025 ANNUAL ELITE PED-GI CONGRESS IN ABU DHABI IN THE UNITED ARAB EMIRATES. MVID AND SBS-IF, RARE ORPHAN DISEASES REQUIRING INTENSIVE PARENTERAL NUTRITION AND SUPPORT, HAVE SEVERE MORBIDITY AND MORTALITY IMPLICATIONS AND IMPACT THE QUALITY OF LIFE OF BOTH PATIENTS AND THEIR CAREGIVERS.

PROOF-OF-CONCEPT DATA FOR RARE DISEASE INDICATIONS MVID AND SBS-IF FOR JAGUAR HEALTH'S CROFELEMER TO BE PRESENTED AT APRIL 2025 ELITE PED-GI CONGRESS

THIS STUDY, INITIATED YESTERDAY, IS ONE OF FIVE CLINICAL EFFORTS - THREE PROOF-OF-CONCEPT (POC) INVESTIGATOR-INITIATED TRIALS (IIT) AND TWO PHASE 2 STUDIES - OF CROFELEMER FOR THE RARE DISEASE INDICATIONS OF SBS-IF AND MICROVILLUS INCLUSION DISEASE (MVID) IN THE US, EU, AND/OR MIDDLE EAST/NORTH AFRICA REGIONS AVAILABILITY OF FIRST IIT PROOF-OF-CONCEPT RESULTS POTENTIALLY IN H1 2025 CROFELEMER, JAGUAR'S NOVEL PLANT-BASED PRESCRIPTION DRUG, HAS BEEN GRANTED ORPHAN-DRUG DESIGNATION BY THE FDA AND THE EUROPEAN MEDICINES AGENCY (EMA) FOR BOTH SBS-IF AND MVID SAN FRANCISCO, CA / ACCESS NEWSWIRE / FEBRUARY 19, 2025 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) ("JAGUAR") FAMILY COMPANIES NAPO PHARMACEUTICALS ("NAPO") AND NAPO THERAPEUTICS TODAY ANNOUNCED THAT THE CLINICAL PROTOCOL FOR NAPO'S PHASE 2 STUDY TO EVALUATE THE EFFICACY OF CROFELEMER, JAGUAR'S NOVEL PLANT-BASED ANTI-SECRETORY PRESCRIPTION DRUG, FOR THE INDICATION OF SBS-IF IN ADULTS HAS RECEIVED REGULATORY CLEARANCE FROM HEALTH AUTHORITIES IN ITALY AND GERMANY, WHERE THE TRIAL WILL BE CONDUCTED. THE STUDY INITIATED YESTERDAY, FEBRUARY 18, 2025.

JAGUAR RECEIVES REGULATORY CLEARANCE IN GERMANY AND ITALY FOR CROFELEMER FOR RARE DISEASE STUDY - SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF)

THE STUDY IS ONE OF FIVE CLINICAL EFFORTS - THREE IIT PROOF-OF-CONCEPT STUDIES AND TWO PHASE 2 STUDIES - OF CROFELEMER FOR THE RARE DISEASE INDICATIONS OF SBS-IF AND/OR MICROVILLUS INCLUSION DISEASE (MVID), AN ULTRARARE CONGENITAL DIARRHEAL DISORDER, IN THE US, EU, AND/OR MIDDLE EAST/NORTH AFRICA (MENA) REGIONS; AVAILABILITY OF IIT PROOF-OF-CONCEPT RESULTS POTENTIALLY IN Q2 2025 CROFELEMER, JAGUAR'S NOVEL PLANT-BASED PRESCRIPTION DRUG, HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY THE FDA AND THE EUROPEAN MEDICINES AGENCY FOR BOTH SBS-IF AND MVID SAN FRANCISCO, CA / ACCESSWIRE / DECEMBER 6, 2024 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) (JAGUAR) FAMILY COMPANY NAPO PHARMACEUTICALS (NAPO) TODAY ANNOUNCED THAT AN INDEPENDENT IIT IN THE U.S. TO EVALUATE THE EFFICACY AND SAFETY OF CROFELEMER, JAGUAR'S NOVEL PLANT-BASED ANTI-DIARRHEAL PRESCRIPTION DRUG, FOR THE RARE DISEASE INDICATION OF SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) IN ADULTS HAS BEGUN. AN OVERVIEW OF THE STUDY CAN BE VIEWED ON THE CLINICALTRIALS.GOV WEBSITE.

U.S. INVESTIGATOR-INITIATED TRIAL (IIT) TO EVALUATE JAGUAR HEALTH'S CROFELEMER FOR SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) BEGINS

BOSTON--(BUSINESS WIRE)--IRONWOOD PHARMACEUTICALS, INC. (NASDAQ: IRWD), A GI-FOCUSED HEALTHCARE COMPANY, WILL PRESENT NEW FINDINGS AT THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) 2024 ANNUAL SCIENTIFIC MEETING AND POSTGRADUATE COURSE FROM SUBGROUP ANALYSES OF THE PRIMARY ENDPOINT OF THE PIVOTAL PHASE III CLINICAL TRIAL, STARS, EVALUATING THE TREATMENT EFFECT OF APRAGLUTIDE BY BASELINE DEMOGRAPHICS AND DISEASE-SPECIFIC CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE.

ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF), ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT ACG 2024

NEW PATENT ISSUED FOR CORE RARE DISEASE TARGET INDICATION FOR CROFELEMER NAPO HAS APPROXIMATELY 230 PATENTS ISSUED AND PENDING JAGUAR IS SUPPORTING INDEPENDENT INVESTIGATOR-INITIATED PROOF-OF-CONCEPT STUDIES OF CROFELEMER FOR THE RARE DISEASE INDICATIONS OF SBS AND MICROVILLUS INCLUSION DISEASE (MVID), AN ULTRARARE CONGENITAL DIARRHEAL DISORDER (CDD), IN THE US, EU, AND MIDDLE EAST/NORTH AFRICA REGIONS, WITH RESULTS EXPECTED BY THE END OF 2024 AND THROUGHOUT 2025 SAN FRANCISCO, CA / ACCESSWIRE / AUGUST 27, 2024 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) (JAGUAR) TODAY ANNOUNCED THAT THE COUNTRY OF JORDAN'S INDUSTRIAL PROPERTY PROTECTION DIRECTORATE HAS ISSUED A NEW PATENT TO JAGUAR FAMILY COMPANY NAPO PHARMACEUTICALS (NAPO) FOR METHODS FOR TREATING SHORT BOWEL SYNDROME (SBS), BILE ACID DIARRHEA, AND DIARRHEA ASSOCIATED WITH SMALL INTESTINE RESECTION OR GALLBLADDER REMOVAL, IN PATIENTS WITH AN INHIBITOR OF CHLORIDE-ION TRANSPORT SUCH AS CROFELEMER, JAGUAR'S NOVEL PLANT-BASED PRESCRIPTION DRUG. "WE ARE VERY PLEASED THAT THIS PATENT HAS BEEN ISSUED AND BELIEVE THAT IT FURTHER ENHANCES OUR INTELLECTUAL PROPERTY PROTECTION FOR CROFELEMER FOR OUR CORE RARE DISEASE TARGET INDICATION OF SBS," SAID LISA CONTE, JAGUAR'S FOUNDER, PRESIDENT, AND CEO.

PATENT ISSUED IN JORDAN BOLSTERS IP PROTECTION FOR JAGUAR HEALTH IN THE TREATMENT OF SHORT BOWEL SYNDROME (SBS)

NEW PATENT ISSUED FOR CORE RARE DISEASE TARGET INDICATION FOR CROFELEMER NAPO HAS APPROXIMATELY 230 PATENTS ISSUED AND PENDING JAGUAR IS SUPPORTING INDEPENDENT INVESTIGATOR-INITIATED PROOF-OF-CONCEPT STUDIES OF CROFELEMER FOR THE RARE DISEASE INDICATIONS OF SBS AND MICROVILLUS INCLUSION DISEASE (MVID), AN ULTRARARE CONGENITAL DIARRHEAL DISORDER (CDD), IN THE US, EU, AND MIDDLE EAST/NORTH AFRICA REGIONS, WITH RESULTS EXPECTED BY THE END OF 2024 AND THROUGHOUT 2025 SAN FRANCISCO, CA / ACCESSWIRE / AUGUST 19, 2024 / JAGUAR HEALTH, INC. (NASDAQ:JAGX) (JAGUAR) TODAY ANNOUNCED THAT HONG KONG'S INTELLECTUAL PROPERTY DEPARTMENT HAS ISSUED A NEW PATENT TO JAGUAR FAMILY COMPANY NAPO PHARMACEUTICALS FOR METHODS FOR TREATING SHORT BOWEL SYNDROME (SBS), BILE ACID DIARRHEA, AND DIARRHEA ASSOCIATED WITH SMALL INTESTINE RESECTION OR GALLBLADDER REMOVAL, IN PATIENTS WITH AN INHIBITOR OF CHLORIDE-ION TRANSPORT SUCH AS CROFELEMER, JAGUAR'S NOVEL PLANT-BASED PRESCRIPTION DRUG. "WE ARE VERY HAPPY THAT THIS PATENT HAS BEEN ISSUED AND BELIEVE THAT IT FURTHER ENHANCES OUR INTELLECTUAL PROPERTY PROTECTION FOR CROFELEMER FOR OUR CORE RARE DISEASE TARGET INDICATION OF SBS," SAID LISA CONTE, JAGUAR'S FOUNDER, PRESIDENT, AND CEO.

Companhia de Saneamento Bsico do Estado de So Paulo - SABESP

SBS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Companhia de Saneamento Bsico do Estado de So Paulo - SABESP

SBS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SBS